Duane Reade Q3
This article was originally published in The Rose Sheet
Executive SummarySales for the third quarter were up 8.2% to $338.6 mil., approximately $11.4 mil. below the company's previous expectations due to economic weakness and slowing growth rate of the prescription sector, retailer announces Oct. 6. The announcement was made ahead of an Oct. 23 Q3 earnings call. Northeast power outage in August resulted in a sales loss of about $3.3 mil., the firm notes. Same store sales for the period improved 3%, with pharmacy same store sales increasing 8.6% and front-end same store sales declining 1.1%. Sales performance during Q3 combined with economic impact have lowered net income to about $.08-$.09 per diluted share versus original expectations of $.15-$.20 per diluted share, retailer adds. Annual sales are now expected to be about $1.39 bil., while diluted EPS will be between $.55-$.61...
You may also be interested in...
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.
Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.
Sanofi follows Janssen in teaming up with HHS' BARDA to develop a COVID-19 vaccine; using technology platform of its Flublok vaccine, Sanofi expects to enter clinical trials in 1 to 1 ½ years.